. 2022 Feb 2;20:eRW6155. doi: 10.31744/einstein_journal/2022RW6155

Table 2. Characteristics of the main studies and their results for the use of glyburide and metformin in cases of gestational diabetes mellitus.

Study	Patients	Intervention and methods	Maternal and neonatal outcomes

			Birth weight	Neonatal hypoglycemia	Need for Caesarean section	Need for intensive care	Apgar score	Macrosomia	↓ Fasting blood glucose	↓ Post-prandial blood glucose	Weight gain in pregnancy
Nachum et al.⁽¹²⁾	104 women 53 GG 51 GM	GG: 2.5-20mg/day GM: 850-2,550mg/ day after meals	p=0.6 M=G*	p=0.09 M>G^†	p=0.7 M=G*		Apgar score>7 p=1 M=G*	>4,000g p=0.6 M=G*	p=0.2 M=G*	p=0.3 M=G*	p=0.8 M=G*
Silva et al.⁽¹³⁾	200 women 96 GG 104 GM	GG: 5-20mg/day GM: 1,000-2,500mg/day	p=0.01 M>G^†	p=0.81 M=G*	p=0.88 M=G*	p=0.94 M=G*	In 1’: p=0.56 Up to 5’: p=0.50 M=G*		p=0.18 M=G*	p=0.98 M=G*	p=0.04 M>G^†
Silva et al.⁽¹⁴⁾	72 women 40 GG 32 GM	GG: 5-20mg/day GM: 500-2,500mg/day	p=0.36 M=G*	p=0.89 M=G*	p=0.91 M=G*	p=0.23 M=G*	In 1’: p=0.57 In 5’: p=0.24 M=G*	>4kg p=0.24 M=G*	p=0.15 M=G*	p=0.10 M=G*	p=0.02 M>G^†
George et al.⁽¹⁵⁾	159 women 80 GG 79 GM	GG: 2.5-15mg/day GM: 500-2,500mg/day		p=0.001 M>G^†				>3.7kg p=0.73 M=G*	p=0.37 M=G*	p=0.28 M=G*
Moore et al.⁽¹⁶⁾	149 women 74 GG 75 GM	GG: 5-20mg/day GM: 500mg-2g/day	p=0.02 M>G^†	p=0.32 M=G*	p=0.02 G>M^‡	p=0.37 M=G*			p=0.23 M=G*	p=0.24 M=G*

GG: Glyburide Group; MG: Metformin Group;

* No significant difference between the use of metformin and glyburide at outcome; ^† metformin was superior to glyburide at outcome; ‡ glyburide was superior to metformin at outcome.